NanoBio has announced that Merck has acquired exclusive rights to NanoBio’s NanoStat nanoemulsion adjuvant for an intranasal respiratory syncytial virus (RSV) vaccine. Merck also acquired non-exclusive rights to the adjuvant for use in an intranasal flu vaccine. The amount of the deal, which includes an upfront payment, milestone payments, and royalties on any sales of the vaccines, was not disclosed.
NanoBio CEO David Peralta said, “We’ve collaborated with Merck on research in RSV since 2011 and are very pleased to broaden our relationship with this license agreement covering vaccine candidates for two respiratory diseases. Merck’s demonstrated leadership in developing and marketing vaccines makes them an ideal partner for NanoBio.”
Read the NanoBio press release.
